L8 Clinical trial PHASE 1-3 Flashcards

1
Q

aim of phase 1 [2]

A
  1. safety and tolerability
  2. PKPD of drug: MTD, dose range, ADRs, route of administration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

all subjects of phase 1 must be _____

A

VOLUNTEERS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

criteria to select volunteers/patients for phase 1? [3]

A
  1. usually male unless disease is gender specific
  2. free of substance abuse
  3. no clinical or laboratory abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

who conduct phase 1?

A

specialist and pharmacologists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

is phase 1 an open or closed trial?

A

open

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what kind of drug cannot be tried on healthy volunteers in phase 1?

A
  • Drugs that are too toxic eg anti-Cancer drugs
    • Those that affect germline cells
    • Drugs to treat rare genetic conditions
      Eg. Anti-HIV drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

aim of phase 2

A

efficacy and safety IN PATIENTS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Is phase 2 open or closed trial?

A

closed aka controlled [have placebo]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

whats the difference between open and closed trial?

A

open: both doctor and volunteer knows what drug you’re taking
closed: volunteer OR doctor doesnt know [single or double blind]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

why do we sometimes need a Phase IIa?

A

it acts as a PILOT clinical trial to evaluate efficacy and safety so do on small grp of patients first

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

causes of bias in clinical trial

A
  1. bias
  2. belief
  3. choice and preferences
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ways to eliminate biases [4]

A
  1. run-in period [to allow patient to return to ‘normal’ state, esp for the illness that come and go]
  2. randomisation
  3. blinding
  4. placebo
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

why do we need randomisation [2]

A
  1. avoid bias
  2. provide basis for statistical testing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

why do we need a run-in period? [2]

A
  • study compliance
  • exclude those with high placebo effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

In phase IIb, do we compare drug with placebo or current drugs in market?

A

BOTH. placebo to see if it works. current drug is want to see if more effective/ less ADR than current drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

does placebo have clinical effect?

A

yes, it can have clinical effects

17
Q

what is wash out period? why is it needed?

A

when patients were on pre-trial medicine. needed to ensure effects of treatment is not carried over to the next

18
Q

do all outcome measures need to be scientifically measurable?

A

no but need to be measurable.

19
Q

what is aim of phase 3?

A

larger scale of phase 2: more countries, more subjects –> determine if there is safety and efficacy issues in people

20
Q

what are the pre-clinical trial info requirements? [6]

A
  1. general pharmacology PKPD
  2. acute toxicity LD50
  3. Chronic toxicity [done in 2 animal species]
  4. Reproductive toxicity
  5. carcinogenicity and mutagenicity
  6. chemical/pharmaceutical data
21
Q

how do we measure safety and tolerability of drug during phase I?

A

-measure and check vital functions: CNS/CVS/lungs
- blood and urine test: drug concentrations
- other parameters: weight/height/body temp etc

22
Q

phase 1 trial can be done at comfort of volunteer’s home. T/F?

A

False. should be in in-patient clinic w comprehensive medical surveillance, emergency and intensive care facilities

23
Q

what are some common medical emergencies from drugs?

A

syncope, hypotension, anaphylaxis, cardiopulmonary arrest, multiple organ failure

24
Q

types of hypersensitivity [2]

A

Localised: rhinitis, asthma, rash etc
Generalised: anaphylactic shock

25
dose escalation is usually ___ times of previous dose at each increment?
2 times
26
by the end of phase 1 clinical trial, we should have results about: [2]
1. safe dosage range 2. optimal administration route + PKPD info
27
duration of phase II is long. T/F?
False. it is short-medium duration
28
is the use of placebo ethical? explain.
depends on disease. some diseases eg. critical illness or dependent on drug for survival should not have placebo
29
why do we need a control group for phase 2?
to eliminate effect of natural variability of disease
30
criteria for outcome measures that will be measured
1. must be applicable and measurable in all participants 2. dont have to be always scientifically measurable, as subjective ones cannot 3.should be capable of unbiased assessment
31
give examples of subjective and objective outcomes
Subjective: mood, sleep, pain Objective: mortality, clinical findngs, lab measures
32
state examples of tools for measuring subjective outcomes [2]
Hamilton depression scale, BECK DI [mood/depression], visual analogue scales [pain]